Acute Renal Injury Sequelae in NICU Graduates (ARISING)
Acute Renal Injury Sequelae in NICU Graduates (ARISING)
批准号:
9899244
负责人:
Namasivayam Ambalavanan
金额:
$35.71万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-04-01 至 2023-03-31
关键词:
AcuteAcute Renal Failure with Renal Papillary NecrosisAdultAgeBiologicalBiological MarkersBirthBlood PressureCaringCessation of lifeChronic Kidney FailureClinical ResearchCohort StudiesCreatinineDataDevelopmentDiagnosisDiastolic blood pressureDisease MarkerDisease ProgressionEconomic BurdenEpidemiologyEventFetal Growth RetardationFibrinogenFrequenciesFundingGestational AgeGlomerular Filtration RateGrantHealthHospitalizationHospitalsHumanIncidenceInfantInjury to KidneyIntervention StudiesKidneyKidney DiseasesKnowledgeLifeMeasurementMeasuresMethodsMindMulti-site clinical studyNational Institute of Diabetes and Digestive and Kidney DiseasesNeonatalNeonatal Intensive Care UnitsOutcomePhysiologyPre-EclampsiaPremature InfantPreparationProspective StudiesProspective cohortProspective cohort studyProteinsProteinuriaRadiology SpecialtyResearch DesignResearch PersonnelRetrospective cohortRiskRisk FactorsSensitivity and SpecificitySerumSiteSpecificityTimeUrineVariantVulnerable Populationsage groupbaseclinical riskevidence basehigh riskhigh risk infantimproved outcomein uteromortalityneonatenoveloutcome predictionpost gamma-globulinspostnatalpre-clinicalprenatalprenatal risk factorprimary outcomeprospectivetherapy design
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The scientific premise for this proposal is that prenatal factors and neonatal acute kidney injury (nAKI)
significantly contribute to chronic kidney disease (CKD) in neonatal intensive care unit (NICU) graduates. Our
preliminary data suggests that up to 25% of neonates develop nAKI, which is associated with mortality and CKD.
This NIDDK Multi-Center Clinical Study Implementation Planning Grant (U34) will enable us to achieve specific
milestones in preparation for a U01-funded, multi-center, prospective cohort study. The Acute Renal Injury
Sequela In NICU Graduates (ARISING) study will prospectively capture serum creatinine (SCr) systematically
during the first postnatal week and during high-risk clinical scenarios in 1000 (125 across 8 GA strata)
neonates admitted to the NICU. The project's central purpose is to bridge fundamental knowledge gaps
in the field by providing reliable and precise methods to diagnose nAKI and predict CKD early in the
life of NICU graduates. We propose the following 3 inter-related but independent specific aims.
Aim 1: Validate a novel 2-stage neonatal AKI definition. The contemporary nAKI definition was not developed
with neonatal kidney physiology in mind. Instead, it was adapted from the adult KDIGO AKI definition. Using a
retrospective cohort, we developed a novel nAKI definition using the optimal SCr thresholds which predict
mortality for different gestational age (GA) groups (≤29 and >29 week GA), and postnatal age (< 7 vs 7 days)
Hypothesis 1a: The NKC mild nAKI definition will have greater sensitivity to predict mortality than the
stage 1 KDIGO definition
Hypothesis 1b: The NKC severe nAKI definition will have better specificity to predict mortality than the
stage 2/3 KDIGO definition
Aim 2: Determine if AKI is independently associated with CKD at 2 years corrected GA (cGA).
Maternal and neonatal risk factors may predispose infants to both nAKI and CKD. We will determine the
attributable risk of nAKI on CKD (estimated GFR<90 ml/min/1.73m2, urine protein/creatinine >0.2, blood
pressure >95th%tile, and/or total kidney volume (TKV) <95th%tile at 2 years corrected gestational age (cGA).
Our hypothesis is that nAKI is associated with a composite CKD after controlling for prenatal factors.
Aim 3: Determine which variable(s) available prior to hospital discharge predict CKD at 2 years cGA.
We will evaluate metrics of kidney health (TKV, BP, proteinuria, cystatin C, SCr and urine kidney biomarkers)
at 38 1 week cGA for preterm and 44 1 weeks cGA for term infants. Our hypothesis is that we can predict
with 90% certainty which infants will have composite CKD at 2 years cGA using biological/radiologic markers of
kidney disease obtained at term cGA.
Answers to these questions are greatly needed to help clinicians provide appropriate and timely care, and help
researchers develop interventions designed to improve outcomes in this vulnerable population.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Let-7b in BPD
-
批准号:10655734
-
项目类别:
-
资助金额:$55.44万
-
财政年份:2023
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Prapela® SVS incubator pad: A cost-effective stochastic vibrotactile device to improve the clinical course of infants with apnea of prematurity.
-
批准号:10576754
-
项目类别:
-
资助金额:$50.02万
-
财政年份:2023
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Vital Signs In Opioid-Exposed Neonates
-
批准号:10493363
-
项目类别:
-
资助金额:$50.77万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
UAB Clinical Site HEAL Neonatal Opioid Withdrawal Pharmacological Treatments
-
批准号:10891299
-
项目类别:
-
资助金额:$22.15万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age
-
批准号:10363406
-
项目类别:
-
资助金额:$148.56万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
UAB Clinical Site HEAL Neonatal Opioid Withdrawal Pharmacological Treatments
-
批准号:10372486
-
项目类别:
-
资助金额:$44.29万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Vital Signs In Opioid-Exposed Neonates
-
批准号:10360908
-
项目类别:
-
资助金额:$51.99万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age
-
批准号:10541156
-
项目类别:
-
资助金额:$152.13万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Pre-Vent Apnea
-
批准号:10006023
-
项目类别:
-
资助金额:$53.71万
-
财政年份:2016
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Pre-Vent Apnea
-
批准号:9762173
-
项目类别:
-
资助金额:$56.38万
-
财政年份:2016
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Pre-Vent Apnea
-
批准号:9168075
-
项目类别:
-
资助金额:$19.53万
-
财政年份:2016
-
负责人:Namasivayam Ambalavanan
-
依托单位:
STOP BPD
-
批准号:9292368
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2015
-
负责人:Namasivayam Ambalavanan
-
依托单位:
STOP BPD
-
批准号:9143795
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2015
-
负责人:Namasivayam Ambalavanan
-
依托单位:
STOP BPD
-
批准号:8996355
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2015
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Alveolar DevMAP
-
批准号:9062496
-
项目类别:
-
资助金额:$73.48万
-
财政年份:2014
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Alveolar DevMAP
-
批准号:8685690
-
项目类别:
-
资助金额:$74.01万
-
财政年份:2014
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Alveolar DevMAP
-
批准号:8870421
-
项目类别:
-
资助金额:$73.5万
-
财政年份:2014
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Azithromycin to prevent BPD in ureaplasma-infected preterms.
-
批准号:8240026
-
项目类别:
-
资助金额:$59.75万
-
财政年份:2011
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Azithromycin to prevent BPD in ureaplasma-infected preterms.
-
批准号:8610334
-
项目类别:
-
资助金额:$57.19万
-
财政年份:2011
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Azithromycin to prevent BPD in ureaplasma-infected preterms.
-
批准号:8015539
-
项目类别:
-
资助金额:$62.29万
-
财政年份:2011
-
负责人:Namasivayam Ambalavanan
-
依托单位: